Evaluation of LEVITRA to Advance the Treatment of Erectile Dysfunction
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00664833 |
Recruitment Status :
Completed
First Posted : April 23, 2008
Last Update Posted : December 9, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Erectile Dysfunction | Behavioral: Levitra (Vardenafil, BAY38-9456) Other: No Education | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 1029 participants |
Allocation: | Randomized |
Intervention Model: | Factorial Assignment |
Masking: | None (Open Label) |
Official Title: | An Open-label, Multi-center, Factorial Design, Cluster-randomized Clinical Study of Vardenafil in Canadian Males With Erectile Dysfunction: Impact of Education of the Primary Care Physician and Patient on Patient Outcomes. |
Study Start Date : | May 2004 |
Actual Study Completion Date : | October 2005 |

Arm | Intervention/treatment |
---|---|
Experimental: Arm 2 |
Behavioral: Levitra (Vardenafil, BAY38-9456)
The Subject received the educational intervention |
Arm 4 |
Other: No Education
No education provided to either the Primary Care Physician (PCP) or the subject. |
Experimental: Arm 3 |
Behavioral: Levitra (Vardenafil, BAY38-9456)
Both the Primary Care Physician (PCP) and the subject received the educational intervention |
Experimental: Arm 1 |
Behavioral: Levitra (Vardenafil, BAY38-9456)
The Primary Care Physician (PCP) received the educational intervention |
- Effect of education of the primary care physician or of the subject, in treating erectile dysfunction with vardenafil, relative to usual care, on the subject's treatment outcome of ED and quality of life. [ Time Frame: 12 weeks ]
- To assess the safety and efficacy of vardenafil in Canadian men, when it is prescribed by the PCP, rather than specialist, and to compare the efficacy in these subgroups of subjects. [ Time Frame: 12 weeks ]
- To assess the effectiveness of the physician education program(s) by means of a questionnaire. [ Time Frame: 12 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Males with erectile dysfunction for more than six months according to the NIH Consensus Statement (the inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance).
- Heterosexual relationship
- The subject must make at least four attempts at sexual intercourse (according to the question in the subject diary: "Was sexual activity initiated with the intention of intercourse?") on four separate days during the untreated baseline period.
- At least 50% of attempts during this period must be unsuccessful, according to the following questions from the subject diary [at least one question should be answered "No"]: "Were you able to achieve at least some erection (some enlargement of the penis)?", "Were you able to insert your penis into your partner's vagina?" and "Did your erection last long enough for you to have successful intercourse?"
Exclusion Criteria:
-
Previous or Current Medical Conditions:
- Any unstable medical, psychiatric or substance abuse disorder that, in the opinion of the Investigator, is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study.
- Presence of penile anatomical abnormalities (eg. penile fibrosis or Peyronie's disease) that in the opinion of the Investigator would significantly impair sexual performance.
- History of surgical prostatectomy (transurethral interventions not excluded).
- Hereditary degenerative retinal disorders such as retinitis pigmentosa.
- Any underlying cardiovascular condition including unstable angina pectoris, that would preclude sexual activity.
- Patients 65 years and older for whom the starting dose of 10 mg is judged by the investigator to be unsuitable.
- Uncontrolled atrial fibrillation/flutter at screening (ventricular response rate of > 100 bpm).
- Severe chronic or acute liver disease, history of moderate or severe hepatic impairment.
- Resting hypotension (a resting systolic blood pressure of <90 mm Hg) or hypertension (a resting systolic blood pressure >170 mm Hg or a resting diastolic blood pressure >110 mm Hg).
- Symptomatic postural hypotension within six months of Visit 1.
- NYHA Class III or IV heart failure
-
Concomitant Medications:
- Subjects who are taking nitrates or nitric oxide donors.
- Subjects who are taking anticoagulants, except for antiplatelet agents.
- Subjects who are taking androgens.
- Subjects who are taking the following inhibitors of cytochrome P 450 CYP 3A4: very potent HIV protease inhibitors (ritonavir, indinavir), the anti-mycotic agents itraconazole and ketoconazole (topical forms are allowed) or erythromycin.
- Subjects who have received any investigational drug (including placebo) within 30 days of Visit 1.
- Use of any treatment for erectile dysfunction within the 7 days of Visit 1 or during the study, including oral medications, vacuum devices, constrictive devices, injections or urethral suppositories.
- Known hypersensitivity to Vardenafil, Bay 38-9456 or any component of the investigational medication.
- Patients with a history of unresponsiveness to other PDE V inhibitor treatments due to lack of efficacy or significant side effects leading to discontinuation of the other PDE V inhibitor.
- Subjects who are taking alpha blockers.
-
Other Exclusions:
- Subjects unwilling to cease use of vacuum devices, intracavernosal injection, Viagra or other therapy for erectile dysfunction.
- Subjects who are unwilling or unable to complete the subject diary.
- Subjects who are illiterate or unable to understand the questionnaires or subject diary.
- Subjects unwilling to refrain from consuming grapefruit juice or products containing grapefruit juice with the study medication.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00664833
Study Director: | Bayer Study Director | Bayer |
Responsible Party: | Medical Affairs Therapeutic Area Head, Bayer HealthCare Pharmaceuticals Inc. |
ClinicalTrials.gov Identifier: | NCT00664833 |
Other Study ID Numbers: |
100537 ELATED |
First Posted: | April 23, 2008 Key Record Dates |
Last Update Posted: | December 9, 2014 |
Last Verified: | December 2014 |
Erectile dysfunction Phosphodiesterase Type 5 Inhibitors Patient education Impotence Vardenafil |
Erectile Dysfunction Sexual Dysfunction, Physiological Sexual Dysfunctions, Psychological Mental Disorders Vardenafil Dihydrochloride Vasodilator Agents |
Phosphodiesterase 5 Inhibitors Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Urological Agents |